March 2012
Volume 53, Issue 14
ARVO Annual Meeting Abstract  |   March 2012
Potential Early Indicators for Visual Outcome in Treatment Naïve Cases with Neovacsular Age-Related Macular Degeneration
Author Affiliations & Notes
  • Ghazala A. Datoo
    Ophthalmology, USC Doheny Eye Institute, Los Angeles, California
  • Florian M. Heussen
    Doheny Eye Institute, Pasadena, California
  • Srinivas R. Sadda
    Ophthalmology, Doheny Eye Institute - USC, Los Angeles, California
  • Footnotes
    Commercial Relationships  Ghazala A. Datoo, None; Florian M. Heussen, None; Srinivas R. Sadda, Allergan (C), Carl Zeiss Meditec (F), Genentech (C), Heidelberg Engineering (C), Optovue, Inc. (F), Topcon Medical System (P)
  • Footnotes
    Support  DFG Grant He 6094/1-1; Beckman Institute for Macular Research; Research to Prevent Blindness Physician Scientist Award.
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 5157. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ghazala A. Datoo, Florian M. Heussen, Srinivas R. Sadda; Potential Early Indicators for Visual Outcome in Treatment Naïve Cases with Neovacsular Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2012;53(14):5157.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

To investigate a potential relationship between clinical parameters and final visual outcome in eyes with neovascular age-related macular degeneration (NVAMD) treated with intravitreal injections of Avastin or Lucentis over 48 weeks.


From a database of AMD cases at our institution we retrospectively selected all eyes with NVAMD that were treated with anti-VEGF injections. All patients were treatment naïve and received intravitreal injections of either Lucentis or Avastin at the clinicians discretion. Medical charts were reviewed for every follow-up until 48 weeks after the initial injection, and demographics as well as data from the ophthalmic examination were collected and transcribed into a digital database. Statistical analyses were performed to explore a relationship between final visual acuity (VA) and: VA at baseline (BSL), 4, 12 and 24 weeks, number of injections during follow-up, first or second eye affected, lens status, and demographic parameters (age, gender).


49 eyes were included in the analysis. 12 eyes showed an improvement in VA of 3 lines or more during the 48 week follow-up, 6 of which as early as 4 weeks after the initial injection. 10 of 49 eyes lost at least one line in VA from BSL to week 48. Interestingly, there was no statistically significant difference in BSL-VA, age, or number of injections during follow-up between eyes that lost vision and eyes that remained stable or gained vision. After backward elimination, the multivariate regression model to predict VA at week 48 yielded VA at week 4 and week 24 as significant parameters (R2 = 0.77, p< 0.001). Univariate regression models with the same dependent variable showed a significant predictive power of VA (p<0.001) at BSL (R2 = 0.46), 4 weeks (R2 = 0.64), 12 weeks (R2 = 0.74) and 24 weeks (R2 = 0.74), while the absolute change in VA was not predictive of final outcome.


The visual acuity within the first 24 weeks after primary intravitreal injection was reflective of the functional results at 48 weeks, while demographic and treatment factors did not seem to play a significant role.

Keywords: age-related macular degeneration 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.